Introduction {#S0001}
============

Cannabis is the most widely used illicit drug in the world.[@CIT0001] Its use is particularly common among children and adolescents. In the US, 37% of 12th graders report using cannabis in the past year,[@CIT0002] with prevalence rising significantly among youth from 23.9% in 1991 to 35.6% in 2016.[@CIT0003] Similarly, one-third of Canadian youth have tried cannabis at least once by age 15.[@CIT0001] The prevalence of cannabis use will likely continue to rise, in part due to recent waves of legalization. In the US, recreational cannabis has been legalized in 11 states, while 33 states allow for some form of legalized medical cannabis.[@CIT0004] Minors under the age of 18 are permitted to apply for medical cannabis cards, given that they have the permission of a physician as well as their guardian.[@CIT0004] Recreational cannabis was legalized in Canada in 2018. All Canadian provinces allow the prescription of medical cannabis. Although Health Canada warns against prescribing cannabis to those under age 25, there is no absolute contraindication based on age; rather, physicians are asked to weigh the potential benefits and risks on a case-by-case basis.[@CIT0005]

Cannabinoids act on two main receptors within the human endocannabinoid system: CB~1~ and CB~2~. CB~1~ is distributed throughout the central nervous system (CNS), with highest concentrations in the amygdala, hippocampus, basal ganglia, and prefrontal cortex.[@CIT0006] It plays a modulatory role in a wide range of critical processes such as nocioception, coordination, learning, rewards, appetite, anxiety, and mood.[@CIT0007] CB~2~ receptors, in contrast, are expressed primarily in peripheral immune tissues.[@CIT0008] More recently, there has been evidence that a third cannabinoid receptor exists, with distinct signaling properties from CB~1~ and CB~2~, although its exact identity and function remain elusive.[@CIT0009],[@CIT0010] Tetrahydrocannabinol (THC) and cannabidiol (CBD), in turn, are the two most studied cannabinoids. THC is the main psychoactive component and a partial CB~1~ and CB~2~ agonist.[@CIT0011] On the other hand, CBD has low affinity to CB~1~ and CB~2~[@CIT0012] and possesses anti-inflammatory and anti-spasmodic benefits without prominent psychoactive effects.[@CIT0013] There are two synthetic cannabinoids approved for medical use -- dronabinol and nabilone -- both of which are chemically similar to THC.[@CIT0014],[@CIT0015] More recently, plant-derived CBD has also been FDA-approved in the form of Epidiolex. Many cannabis products also contain varying concentrations of other bioactive ingredients such as terpenoids and flavonoids, which are beyond the scope of this paper; for more information regarding their properties and potential effects in pain, readers are encouraged to refer to reviews by Baron[@CIT0016] and Russo.[@CIT0017]

As cannabinoids are involved in such a wide array of CNS and immune processes, there has been growing interest in their use in medicine, particularly for pain management. While some evidence supports medical cannabis use in adults with neuropathic pain,[@CIT0018]--[@CIT0020] less is known about the safety and efficacy of medical cannabis in pediatric patients. Therefore, in this paper we aimed to provide an overview of the efficacy and safety of medical cannabis for pain relief in children and youth. We discuss the prevalence and characteristics of medical cannabis use in this population, as well as its benefits and harms. Lastly, we discuss patients' and health-care providers' perception of medical cannabis, and provide recommendations for future research in this area.

Methods {#S0002}
=======

We searched PubMed, PsychInfo, Web of Science, and CINAHL using the following search terms: ("cannabis" or "cannabinoid\*" or "marijuana" or "CBD" or "THC") AND ("pediatric\*" or "paediatric\*" or "child" or "children" or "teen\*" or "adolescent\*" or "youth\*" or "young adult\*") AND pain. Article titles and abstracts were screened by three reviewers (JW, TR, and EVR). Articles were included if they studied one of the following: prevalence or characteristics of medical cannabis use; efficacy of medical cannabis for pain relief; short- or long-term risks of medical or recreational cannabis; and beliefs, attitudes, and perceptions of patients, families, and healthcare regarding medical cannabis. Only studies on children and youth (aged 24 and below) were included. Non-English articles were excluded.

Prevalence and Characteristics of Medical Cannabis Use Among Children and Youth {#S0003}
===============================================================================

Estimates of the prevalence and patterns of pediatric medical cannabis use vary. A 2012--13 US survey of 4579 12th graders found medical cannabis use prevalence of 1.1%.[@CIT0021] Medical users accounted for 3% of all youth who used cannabis in the past year.[@CIT0021] In Colorado and Washington, individuals under age 18 make up 0.39--1% of all patients with medical cannabis registration.[@CIT0022],[@CIT0023] On the other hand, in a study of 6509 students in California, 28% of those who had used cannabis in the last 30 days held a medical cannabis card.[@CIT0024]

Seizures and severe pain are the most commonly reported reasons for using medical cannabis in children aged 0--10 and 11--17 years, respectively.[@CIT0022] There do not appear to be significant sociodemographic differences between youth who use cannabis medically and recreationally.[@CIT0025] However, medical cannabis patients are 1.6 times more likely to report pain conditions, 1.4 times more likely to report neurological conditions, and twice as likely to report mental health issues than young adults who use cannabis recreationally.[@CIT0025]

With respect to characteristics of use, Tucker et al reported that among 671 adolescents aged 13--19 using cannabis in California, having a medical cannabis card was associated with greater quantity and frequency of use, as well as greater risk of cannabis-associated problems including: driving under the influence of cannabis (DUIC), missing school or work, and lower performance in school.[@CIT0024] Those with medical cannabis cards were also more likely to report having felt the need to cut down or quit cannabis in the last three months.[@CIT0024] Results remained consistent even after controlling for self-reported physical and mental health status.[@CIT0024] On the other hand, Fedorova et al found that medical cannabis use was negatively associated with illicit drug use in young adults aged 18--26.[@CIT0026] This is consistent with findings from the adult literature that those who use cannabis medically are less likely to use illicit substances,[@CIT0027],[@CIT0028] and that some medical cannabis patients are utilizing cannabis as a substitute for other substances such as alcohol, opioids, and illicit drugs.[@CIT0029]--[@CIT0031]

Self-Medicating with Cannabis {#S0003-S2001}
-----------------------------

Some studies show that children and youth describe using cannabis to self-medicate. In a survey of 169 young adults using cannabis, there were 41 mentions of self-medication for pain, 79 for anxiety, and 44 for depression.[@CIT0006],[@CIT0032] In a sample of young adult cannabis users with history of trauma, severity of PTSD symptoms was significantly associated with using cannabis for coping.[@CIT0033] Thus, the aforementioned epidemiological data may not capture a large number of children and youth self-medicating with cannabis.

Efficacy of Medical Cannabis in Pain Management Among Children and Youth {#S0004}
========================================================================

A recent systematic review identified just one study -- a case report -- on the efficacy of medical cannabis in pain management among children and youth.[@CIT0034] This report trialed dronabinol in two adolescents with chronic neuropathic pain and refractory major depressive disorder.[@CIT0034] The first participant reported 45% improvement in pain intensity, while the second reported no improvement. In both, four months of dronabinol was associated with 50% improvement in the affective component of pain, in that they found their pain to be less debilitating. Participants also perceived improvements in mood, sleep, activities of daily life, academic performance, and relationships. However, the perceived benefits of dronabinol gradually dissipated, leading to its discontinuation in 12 months at the patients' request.[@CIT0034]

Similar, modest improvements in pain were found in a small, non-controlled study that examined CBD and THC in 25 patients aged 1--17 years with complex motor disorders.[@CIT0035] Two formulations of Avidekel whole plant CBD-enriched 5% oil extract were used: CBD-to-THC ratio 6:1 and CBD-to-THC ratio 20:1.[@CIT0035] After five months, participants reported a 1.41-point reduction in pain on a 10-point scale (p = 0.02).[@CIT0035] Statistically significant improvements were also seen in dystonia, spasticity, motor function, quality of life, mood, appetite, and sleep.[@CIT0035] Notably, the analyses were not adjusted for multiple comparison error, despite the study having included more than 36 comparisons.

More evidence exists for medical cannabis in adults. The 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report on cannabis found substantial evidence that cannabis is effective for chronic pain management among adults.[@CIT0036] Similarly, a review of trials on inhaled THC found a dose-dependent effect on neuropathic pain, with similar effect sizes (number needed to treat (NNT) 5.6 \[95% CI 3.4--14\]) as gabapentin (NNT 5.9 \[95% CI 4.6--8.3\]).[@CIT0020] No randomized-controlled trial to date has commented on long-term efficacy of medical cannabis (defined as longer than 26 weeks), and thus it is unclear whether these benefits persist over time.[@CIT0019] It is also unclear whether the benefits demonstrated in adult studies are generalizable to the youth population.

Risks {#S0005}
=====

Medical Cannabis Literature {#S0005-S2001}
---------------------------

A systematic review of medical cannabis in children and adolescents found that the most common adverse effects of THC and CBD are drowsiness, dizziness, diarrhea, and increased appetite; all of which seem to improve with dose reduction.[@CIT0037] More recently, a small observational study of patients aged 1--17 years with complex motor disorders found that CBD and THC were associated with serious adverse events in five out of 25 participants, including behavioral change, somnolence, and worsening seizures.[@CIT0035] All serious adverse events were reversible through dose reduction.[@CIT0035] In adults, a Cochrane systematic review on medical cannabis for neuropathic pain found greater prevalence of adverse CNS events (61% vs 29%; number needed to harm (NNTH) 3 \[95% CI 2--6\]) and adverse psychiatric symptoms (17% vs 5%; NNTH 10 \[95% CI 7--16\]) in the intervention group compared to placebo.[@CIT0019] Patients receiving medical cannabis were more likely to withdraw from studies due to adverse events compared to those receiving placebo (10% vs 5%; NNTH 25 \[95% CI 16--50\]).[@CIT0019]

Overall, no randomized-controlled trial in pediatric or adult populations has commented on long-term risks of medical cannabis. Two observational, open-label extension studies in adults found no increase in the frequency or severity of adverse effects over 32- and 38-week periods, respectively.[@CIT0038],[@CIT0039] Apart from one participant showing mild signs of dependence, there were no other reports of tolerance or abuse.[@CIT0038],[@CIT0039]

Recreational Cannabis Literature {#S0005-S2002}
--------------------------------

Due to the scarcity of evidence on the safety of medical cannabis in children and youth, we also outline findings from the literature on recreational cannabis.

### Cognition {#S0005-S2002-S3001}

A meta-analysis of 69 studies on 2515 cannabis users and 6575 controls (mean age 20 years) found heavy or frequent cannabis use to be associated with lower performance in neurocognitive testing However, the effect size was small (mean d −0.25, 95% CI −0.32 to −0.17) and transient; it became negligible when users abstained from cannabis for 72 hours (mean d −0.08, 95% CI −0.22 to 0.07).[@CIT0040]

### Driving {#S0005-S2002-S3002}

Cannabis is the illicit drug most frequently implicated in impaired driving, and younger age is a risk factor for DUIC.[@CIT0041] Four meta-analyses found DUIC to be linked with increased risk of motor vehicle collisions, although there was a wide range in the estimated effect sizes (20--266%).[@CIT0042]--[@CIT0045] There is a dose-dependent relationship between THC and the level of impairment on driving.[@CIT0046]

### Mood and Anxiety {#S0005-S2002-S3003}

In a meta-analysis of 11 studies on 23,317 adolescents, cannabis use during adolescence was associated with increased adulthood risk of depression (OR 1.37, 95% CI 1.16--1.62), suicidal ideation (OR 1.50, 95% CI 1.11--2.03), and suicidal attempt (OR 3.46, 95% CI 1.53--7.84), but not with anxiety (OR 1.18, 95% CI 0.84--1.67).[@CIT0047] These results were adjusted for age, sex, socioeconomic status, alcohol, smoking, and baseline anxiety or depression symptoms.[@CIT0047]

### Psychosis {#S0005-S2002-S3004}

Cannabis users commonly experience acute, transient symptoms of psychosis such as paranoia and hallucinations.[@CIT0048] Recently there has been substantial evidence that cannabis use is also linked with development of psychotic disorders such as schizophrenia.[@CIT0036] A 2016 meta-analysis involving 10 studies and 66,816 participants found a dose-dependent relationship between cannabis use and risk of psychotic symptoms (OR 3.59, 95% CI 2.42--5.32) as well as diagnoses of schizophrenia or other psychotic disorders (OR 5.07, 95% CI 3.62--7.09).[@CIT0049] Participants with baseline psychotic symptoms were excluded from analyses. The analyses were not adjusted for confounders; however, two studies that did control for confounders (e﻿g, ethnicity, sex, early emotional or behavioral problems, and use of other substances) confirmed this association.[@CIT0050],[@CIT0051] Interestingly, cannabis use is not associated with worsening of negative symptoms of schizophrenia.[@CIT0036]

Despite these findings, it is difficult to draw a causal relationship between cannabis and psychosis; instead, the relationship between cannabis and psychotic disorders is likely multifactorial. In fact, substance use disorders and mental illness are generally considered to be risk factors for one another and share significant overlap in underlying neurochemical and neurobiological pathways.[@CIT0036],[@CIT0048] In particular, patients with schizophrenia often exhibit negative symptoms years prior to the onset of psychosis; thus, it's possible that early cannabis use history reflects self-medication for prodromal symptoms of schizophrenia, as opposed to the underlying cause of schizophrenia.[@CIT0052] In addition, predisposing factors such as genetic and environmental vulnerabilities may place certain individuals at increased risk of both cannabis use and psychosis.[@CIT0036]

### Tolerance and Other Drug Use {#S0005-S2002-S3005}

A recent systematic review reported that repeated cannabis exposure leads to tolerance, with greatest tolerance to cognitive effects and partial tolerance to psychoactive and cardiac effects.[@CIT0053] Further, 8.9% of cannabis users eventually meet diagnostic criteria for cannabis use disorder,[@CIT0054] with greater risk (17%) seen in those who started using before adulthood.[@CIT0055] There are also concerns that cannabis can lead to use of other substances, acting colloquially as a "gateway drug". The 2017 NASEM report found moderate-quality evidence of a link between cannabis use and increased risk of developing substance use disorder for other substances, including alcohol, tobacco, and illicit drugs.[@CIT0036] For instance, after adjusting for covariates (ex. early tobacco/alcohol use, conduct disorder, depression, and social anxiety), one twin study found that those who used cannabis by age 17 were significantly more likely to develop alcohol (OR 1.85, 95% CI 1.21--2.83), stimulant (OR 3.79, 95% CI 1.60--9.01), or opioid (OR 5.00, 95% 1.10--22.82) use disorder compared to their twin controls.[@CIT0056] Interestingly, early cannabis use was only marginally associated with increased risk of cannabis use disorder after adjusting for covariates (OR 1.57, 95% 0.98--2.52).[@CIT0056]

On the other hand, there is some evidence that cannabis use is associated with reduced use of other harmful substances. In a longitudinal study of street-involved youth, daily cannabis use was negatively associated with the use of IV stimulants.[@CIT0057] In a survey of 2032 Canadian medical cannabis users, 69% reported using cannabis as a substitute for prescription drugs (35% of which were for opioids), 44% for alcohol, 31% for tobacco, and 27% for illicit substances.[@CIT0029] Of those who mentioned substituting for opioids, 59% reported total cessation of opioid use after initiating medical cannabis.[@CIT0029] At the population level, a 2014 study found 24.5% lower rates of opioid overdose mortality in states with medical cannabis laws compared to those without legalized medical cannabis (95% CI −37.5% to −9.5%).[@CIT0031] However, when this analysis was extended through a longer period (up to 2017), the relationship between medical cannabis laws and opioid overdose appeared to reverse directions; states that legalized medical cannabis experienced a 22.7% increase in opioid overdose mortality rates (95% CI 2.0--47.6%).[@CIT0058] Most recently, a 2019 systematic review and meta-analysis of adults with opioid use disorder found no effect of cannabis use in opioid use.[@CIT0059] Therefore, findings on this topic continue to be too mixed and scarce to allow strong conclusions.

### Drug-Drug Interactions {#S0005-S2002-S3006}

Antidepressants, antipsychotics, anticonvulsants, and proton pump inhibitors are some of the most commonly prescribed medications among children and youth (estimated prevalence of 1.2%, 0.9%, 0.8%, and 0.6%, respectively).[@CIT0060] They can also have significant drug-drug interactions with THC; co-administration with THC results in increased bioavailability and adverse effects of these medications.[@CIT0061] Moreover, fluoxetine -- the most commonly used antidepressant in pediatrics[@CIT0060] -- inhibits the metabolism of THC, thus resulting in increased risk and severity of the THC adverse effects mentioned previously.[@CIT0061] This is particularly concerning considering that a large number of children and youth may be self-medicating with cannabis without consulting a physician, thus increasing the risk of potential drug-drug interactions. So far, no data are available on what proportion of children and youth are reporting their cannabis use (either recreational or medical) to their health-care providers.

Patient and Provider Perspectives of Medical Cannabis {#S0006}
=====================================================

To date, two qualitative studies have explored children and youth's attitudes and beliefs about self-medicating with cannabis.[@CIT0062],[@CIT0063] The first study interviewed 20 individuals aged 13--18 in British Columbia, Canada who were using cannabis without prescription to manage various physical and mental health conditions.[@CIT0062] Five teens reported using cannabis for pain, including pain from muscle injury, burns, headaches, and menstruation. Participants frequently described cannabis as a "natural" product that is safer than conventional pharmacotherapy. Despite perceived benefits, participants were concerned over potential harm to their immune system, energy, memory, cognition, and school performance. Many teens consumed cannabis several times a day, with some using prior to school; these teens referred to cannabis as a "need" or an "addiction". Regardless, the majority were unconcerned with their use.[@CIT0062]

Similar results were documented in a qualitative, Canada-wide report of 77 youth aged 14--19.[@CIT0063] Positive effects on body and mind were one of the most frequently reported reasons for using cannabis. Adolescents described using cannabis to manage their stress, arthritis, pain, seizures, cancer, and mental illness. Many also perceived cannabis to be a healthier and more "natural" alternative to other medications. Youth acknowledged the potential for cannabis to harm their "brain cells" as well as motivation, memory, and mental health. Respondents suggested that better understanding of the risks of cannabis would not change their patterns of use.[@CIT0063]

In terms of health-care provider perspectives, a study of 288 pediatric oncologists in the US showed that just 5% of providers were aware of state-specific regulations pertaining to cannabis.[@CIT0064] However, 30% had received at least one request for medical cannabis in the past month, 26% of which were for pain. Only 8% reported ever suggesting medical cannabis to patients, and most felt that cannabis should be reserved for palliative or treatment-refractory cases only. Providers reported many barriers to authorizing medical cannabis, including the lack of familiarity around its dosing and safety.[@CIT0064]

Similarly, several professional organizations such as the Canadian Psychiatric Association,[@CIT0065] American Academy of Pediatrics,[@CIT0066] and Canadian Pediatric Association,[@CIT0067] have all published official statements warning of the lack of data on efficacy and safety of medical cannabis in the pediatric population. The Canadian Pediatric Society stated that "\"overall, there are insufficient data to support the efficacy or safety of cannabis use for any indications in children, and an increasing body of data suggests possible harm ... \"[@CIT0068]"

and later urged policymakers and physicians to limit pediatric access to medical or recreational cannabis until further evidence becomes available.[@CIT0067]

Discussion and Conclusion {#S0007}
=========================

Based on the current literature, there is insufficient evidence to support routine use of medical cannabis for pain in children and youth. The potential risks of cannabis are significant, compared to the sparse evidence for its benefits in pain management. To date, only two studies (a case report and a small observational study) have examined the effects of cannabis on pain in this population.[@CIT0034],[@CIT0035] Both studies were of poor quality, making it impossible to draw strong conclusions about efficacy. Known short-term adverse effects of medical cannabis are mostly mild, and can be managed through dose reduction.[@CIT0018],[@CIT0037] However, no controlled trial has commented on long-term safety of medical cannabis.[@CIT0035],[@CIT0037] Findings from recreational cannabis literature demonstrate significant short- and long-term harms, such as increased risk of lung cancer and COPD,[@CIT0069] impaired driving,[@CIT0042]--[@CIT0045] depression,[@CIT0047] suicidality,[@CIT0047] psychosis,[@CIT0049] and tolerance.[@CIT0053]

The mechanisms of action behind most of these risks are poorly understood. One possibility is that those with an underlying genetic vulnerability are at greater risk of facing adverse effects of cannabis, such as psychosis. For instance, a post-mortem mRNA expression study found increased CB~1~ binding in the dorsolateral prefrontal cortex of patients with paranoid schizophrenia compared to controls.[@CIT0070] There is also some evidence that certain genetic polymorphisms (such as *AKT1*) are implicated in the association between cannabis and psychosis.[@CIT0071]

Interestingly, there is a discrepancy between patients' and providers' perceptions of medical cannabis. While clinicians are generally cautious of using cannabis for pain in this population,[@CIT0064]--[@CIT0068] many children and youth are already self-medicating with cannabis without guidance from health-care professionals.[@CIT0032],[@CIT0033],[@CIT0062],[@CIT0063] Studies have elucidated common misperceptions among youth, such as: cannabis is "natural" and thus safer than other forms of pharmacotherapy; cannabis is effective for pain control; and there are no serious harms associated with regular cannabis use.[@CIT0062],[@CIT0063] These results clearly indicate a need for better evidenced-based education about cannabis for children and youth.

One important caveat in interpreting this literature is that not all findings from studies of recreational cannabis may be applicable to medical cannabis. Patterns or frequency of use, doses, and concentrations of CBD and THC may vary between recreational and medical users. Moreover, while there is some evidence that cannabis is beneficial for neuropathic pain in adults,[@CIT0018],[@CIT0019] one cannot simply extrapolate these findings to children and youth. As previously mentioned, the endocannabinoid system is under active development during childhood and adolescence, and little is known about the long-term effects of cannabis exposure on the developing brain. Furthermore, certain adverse effects such as depression, psychosis, suicidal behavior, and poor school performance may be particularly detrimental to young people, given their potential to impact important long-term outcomes.

Furthermore, the literature on the prevalence and characteristics of medical cannabis use in children and youth continues to be scarce, with studies using widely different sampling methods and populations -- making it challenging to draw any conclusions about the prevalence of and common indications for use. Similarly, there is limited research on patient and provider perspectives. The two studies that explored perspectives of children and youth were relatively small, qualitative studies.[@CIT0062],[@CIT0063] There was only one study that explored provider perspectives on this topic, and it used a highly specific sample of US pediatric oncologists.[@CIT0064] Both sets of studies make it difficult to draw population-wide generalizations about patient or provider perspectives.

Another major limitation in the literature is that no controlled trial has commented on efficacy or safety of medical cannabis in pain management beyond 26 weeks in pediatric or adult populations. While two open-label extension studies in adults reported continued pain improvement and no increase in adverse events after 32 and 38 weeks,[@CIT0038],[@CIT0039] these studies were at high risk of bias.

Lastly, it is difficult to draw generalizations across the wide range of existing cannabis products. Products vary greatly in terms of their concentrations of CBD and THC,[@CIT0072] which in turn have different mechanisms of action and psychoactive properties. Further, there is no standardized dosing or regimen for medical cannabis, making it even more challenging to draw conclusions from the literature or for providers to make evidenced-based suggestions for patients.

Going forward, well-designed randomized-controlled trials using standardized measures of pain are needed to establish the efficacy of medical cannabis in pain management among children and youth. Future studies should comment on both short- and long-term risks of medical cannabis, accounting for a variety of domains including medical, neuropsychiatric, cognitive, and social. With growing interest in this field, we also expect future studies to explore predictors of treatment benefit and adverse outcomes, which will in turn allow for more individualized clinical decision-making. Lastly, there is a need for further explorations of public perception of medical cannabis, to better understand the rationale for common misperceptions such as cannabis being "safer" and more "natural" than other medications. Elucidating patients' and families' beliefs, concerns, and needs will help guide future research and allow physicians to better counsel and educate patients on this issue.
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